» Articles » PMID: 36007057

Practical Identifiability Analysis of a Mechanistic Model for the Time to Distant Metastatic Relapse and Its Application to Renal Cell Carcinoma

Overview
Specialty Biology
Date 2022 Aug 25
PMID 36007057
Authors
Affiliations
Soon will be listed here.
Abstract

Distant metastasis-free survival (DMFS) curves are widely used in oncology. They are classically analyzed using the Kaplan-Meier estimator or agnostic statistical models from survival analysis. Here we report on a method to extract more information from DMFS curves using a mathematical model of primary tumor growth and metastatic dissemination. The model depends on two parameters, α and μ, respectively quantifying tumor growth and dissemination. We assumed these to be lognormally distributed in a patient population. We propose a method for identification of the parameters of these distributions based on least-squares minimization between the data and the simulated survival curve. We studied the practical identifiability of these parameters and found that including the percentage of patients with metastasis at diagnosis was critical to ensure robust estimation. We also studied the impact and identifiability of covariates and their coefficients in α and μ, either categorical or continuous, including various functional forms for the latter (threshold, linear or a combination of both). We found that both the functional form and the coefficients could be determined from DMFS curves. We then applied our model to a clinical dataset of metastatic relapse from kidney cancer with individual data of 105 patients. We show that the model was able to describe the data and illustrate our method to disentangle the impact of three covariates on DMFS: a categorical one (Führman grade) and two continuous ones (gene expressions of the macrophage mannose receptor 1 (MMR) and the G Protein-Coupled Receptor Class C Group 5 Member A (GPRC5a) gene). We found that all had an influence in metastasis dissemination (μ), but not on growth (α).

Citing Articles

Radiation necrosis after radiation therapy treatment of brain metastases: A computational approach.

Ocana-Tienda B, Leon-Triana O, Perez-Beteta J, Jimenez-Sanchez J, Perez-Garcia V PLoS Comput Biol. 2024; 20(1):e1011400.

PMID: 38289964 PMC: 10857744. DOI: 10.1371/journal.pcbi.1011400.


Experimental and computational modeling for signature and biomarker discovery of renal cell carcinoma progression.

Cooley L, Rudewicz J, Souleyreau W, Emanuelli A, Alvarez-Arenas A, Clarke K Mol Cancer. 2021; 20(1):136.

PMID: 34670568 PMC: 8527701. DOI: 10.1186/s12943-021-01416-5.

References
1.
KUNDEL H . Predictive value and threshold detectability of lung tumors. Radiology. 1981; 139(1):25-9. DOI: 10.1148/radiology.139.1.7208937. View

2.
Norton L . A Gompertzian model of human breast cancer growth. Cancer Res. 1988; 48(24 Pt 1):7067-71. View

3.
Benzekry S, Tracz A, Mastri M, Corbelli R, Barbolosi D, Ebos J . Modeling Spontaneous Metastasis following Surgery: An In Vivo-In Silico Approach. Cancer Res. 2015; 76(3):535-47. PMC: 5846333. DOI: 10.1158/0008-5472.CAN-15-1389. View

4.
Lee S, Sung H, Jeon H, Jeong B, Jeon S, Lee H . Size and Volumetric Growth Kinetics of Renal Masses in Patients With Renal Cell Carcinoma. Urology. 2016; 90:119-24. DOI: 10.1016/j.urology.2015.10.051. View

5.
Yousefi S, Amrollahi F, Amgad M, Dong C, Lewis J, Song C . Predicting clinical outcomes from large scale cancer genomic profiles with deep survival models. Sci Rep. 2017; 7(1):11707. PMC: 5601479. DOI: 10.1038/s41598-017-11817-6. View